Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of subcutaneous Cup a 1 immunotherapy in Cupressaceae pollen allergy
2022-000615-31Phase 3Active
- Sponsor
- Laboratorios Diater
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Cup a 1 purified and isolated protein in allergic rhinoconjunctivitis (ARC) and asthma (2 arms), sponsored by Laboratorios Diater. Primary endpoint: Combined Symptom and Medication Score. Started Feb 2022; status: active.
02
Drugs
Cup a 1 purified and isolated protein
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2022-000615-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000615-31.